| Year |
Citation |
Score |
| 2018 |
Nasir A, Falcon BL, Wang D, Holzer TR, Nonte EM, Chen MY, Fulford AD, Carter JH, Douglass LE, Pytowski B, Bell-McGuinn KM, Walgren RA, Schade AE, Chaudhry A. Vascular and tumor cell expression of VEGFR2 and molecular subtyping: An innovative biomarker approach in bladder cancer. Journal of Clinical Oncology. 36: 497-497. DOI: 10.1200/Jco.2018.36.6_Suppl.497 |
0.371 |
|
| 2018 |
LeBlanc AK, Oakley GJ, Lowery CD, Mendoza A, Ren L, Holzer T, Credille K, Winings C, Estelle A, Chen M, Finnegan P, Blosser W, Schade A, Melemed S, Stancato LF. Abstract LB-B01: The anti-platelet-derived growth factor receptor α antibody olaratumab (Lartruvo) increases overall survival in metastatic mouse models of human osteosarcoma Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-B01 |
0.323 |
|
| 2016 |
Holzer TR, O'Neill Reising L, Credille KM, Schade AE, Oakley GJ. Variability in Platelet-Derived Growth Factor Receptor Alpha Antibody Specificity May Impact Clinical Utility of Immunohistochemistry Assays. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. PMID 27837159 DOI: 10.1369/0022155416673979 |
0.322 |
|
| 2015 |
Holzer TR, Nedderman DM, Nasir A. Abstract 4175: Robust immunohistochemical assay to characterize human cancer tissues for prevalence of vascular endothelial growth factor receptor 3 (VEGFR3) Cancer Research. 75: 4175-4175. DOI: 10.1158/1538-7445.Am2015-4175 |
0.363 |
|
| 2015 |
Nasir A, Holzer TR, Man M, Benjamin LE, Melemed AS, Schade AE. Abstract 4161: Differential expression of VEGFR2 Protein in HER2 positive primary human breast cancer: Potential relevance to newer anti-angiogenic therapies Cancer Research. 75: 4161-4161. DOI: 10.1158/1538-7445.Am2015-4161 |
0.351 |
|
| 2015 |
Holzer TR, Fulford AD, Reising LO, Nedderman DM, Benjamin LE, Schade AE, Nasir A. Abstract 4157: Heterogeneity of vascular endothelial growth factor receptors 1, 2, and 3 in human non-small cell lung carcinomas Cancer Research. 75: 4157-4157. DOI: 10.1158/1538-7445.Am2015-4157 |
0.373 |
|
| 2014 |
Yan SB, Um SL, Peek VL, Thobe MN, Credille KM, Stephens JR, Manro JR, Ballard DW, Baker JA, Cook JD, Konicek BW, Graff JR, Holzer TR, Walgren RA. Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models Cancer Research. 74: 4403-4403. DOI: 10.1158/1538-7445.Am2014-4403 |
0.344 |
|
| 2014 |
Holzer TR, O'Neill LA, Nedderman DM, Fulford AD, Falcon BL, Uhlik MT, Benjamin LE, Schade AE, Nasir A. Abstract 3007: Heterogeneity of vascular endothelial growth factor receptors 1, 2, and 3 in primary human colorectal adenocarcinoma Cancer Research. 74: 3007-3007. DOI: 10.1158/1538-7445.Am2014-3007 |
0.367 |
|
| 2014 |
Holzer TR, Falcon BL, Fulford AD, McDonald SA, Ray AL, Finnegan P, Uhlik MT, Benjamin LE, Schade AE, Nasir A. Abstract 3004: VEGFR2 expression and vascular phenotyping demonstrate different patterns of tumor angiogenesis in human gastric and breast cancers Cancer Research. 74: 3004-3004. DOI: 10.1158/1538-7445.Am2014-3004 |
0.307 |
|
| 2013 |
Holzer TR, Fulford AD, Nedderman DM, Umberger TS, Hozak RR, Joshi A, Melemed SA, Benjamin LE, Plowman GD, Schade AE, Ackermann BL, Konrad RJ, Nasir A. Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung. Plos One. 8: e80292. PMID 24244672 DOI: 10.1371/Journal.Pone.0080292 |
0.389 |
|
| 2011 |
Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6582-91. PMID 21831956 DOI: 10.1158/1078-0432.Ccr-11-0430 |
0.336 |
|
| 2010 |
Holzer TR, Heinz-Taheny K, Ballard DW, Powell EL, Dolled-Filhart MP, Christiansen J, Gustavson M, Biryukov J, Virayah J, Pratt SE, Shepard RL, Busbice SCD, Dantzig AH. Abstract B31: Potential for patient tailoring for prodrug of gemcitabine (LY2334737) by assessment carboxylesterase II expression in solid tumor biopsies Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B31 |
0.442 |
|
| 2008 |
Holzer TR, Mishra KK, LeBowitz JH, Forney JD. Coordinate regulation of a family of promastigote-enriched mRNAs by the 3'UTR PRE element in Leishmania mexicana. Molecular and Biochemical Parasitology. 157: 54-64. PMID 18023890 DOI: 10.1016/J.Molbiopara.2007.10.001 |
0.611 |
|
| 2007 |
Cohen-Freue G, Holzer TR, Forney JD, McMaster WR. Global gene expression in Leishmania. International Journal For Parasitology. 37: 1077-86. PMID 17574557 DOI: 10.1016/J.Ijpara.2007.04.011 |
0.625 |
|
| 2006 |
Holzer TR, McMaster WR, Forney JD. Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana. Molecular and Biochemical Parasitology. 146: 198-218. PMID 16430978 DOI: 10.1016/J.Molbiopara.2005.12.009 |
0.63 |
|
| 2003 |
Mishra KK, Holzer TR, Moore LL, LeBowitz JH. A negative regulatory element controls mRNA abundance of the Leishmania mexicana Paraflagellar rod gene PFR2. Eukaryotic Cell. 2: 1009-17. PMID 14555483 DOI: 10.1128/Ec.2.5.1009-1017.2003 |
0.505 |
|
| Show low-probability matches. |